G01N 2333/5443
Il-15
G01N2333/5443 (Il-15) appears on 24 US grants and 47 published applications in this corpus.
Search patents in G01N- Granted patents
- 24
- Published applications
- 47
- Assignees
- 42
- Inventors
- 102
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 1 |
| 2003 | 0 | 0 |
| 2004 | 1 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 1 | 0 |
| 2009 | 0 | 1 |
| 2010 | 0 | 1 |
| 2011 | 1 | 0 |
| 2012 | 0 | 2 |
| 2013 | 0 | 0 |
| 2014 | 1 | 2 |
| 2015 | 0 | 4 |
| 2016 | 0 | 2 |
| 2017 | 2 | 3 |
| 2018 | 3 | 4 |
| 2019 | 1 | 1 |
| 2020 | 2 | 2 |
| 2021 | 1 | 1 |
| 2022 | 2 | 4 |
| 2023 | 2 | 5 |
| 2024 | 1 | 3 |
| 2025 | 2 | 5 |
| 2026 | 4 | 5 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Drug-specific pharmacokinetic assay for IL-15 superagonist6 Oct 2026US 12,754,189 B2NantCell, Inc.
- Cytokine-based therapies and methods30 Jun 2026US 12,668,627 B2Reverb Therapeutics, Inc.
- Diagnostic methods for t cell therapy24 Feb 2026US 12,559,718 B2
- Methods of detecting and treating cerebral aneurysms17 Feb 2026US 12,553,904 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Biomarker panels for on-treatment prediction of response to immuno-oncology drugs30 Sep 2025US 12,429,485 B2The Brigham and Women S Hospital, Inc.
- Novel cytokine-based therapies and methods17 Sep 2026US 2026/0274943 A1Reverb Therapeutics, Inc.
- Systemic biomarkers for the dynamic assessment of tumor burden and treatment efficacy in high grade gliomas2 Jul 2026US 2026/0188489 A1Mary Hitchcock Memorial Hospital, for itself and on behalf of Dartmouth-Hitchcock Clinic
- Antibodies that specifically bind to human il-15 and uses thereof4 Jun 2026US 2026/0152548 A1Cephalon, Inc.
- Development and Use of Novel Interleukin 15 Mutant Polypeptide26 Feb 2026US 2026/0055153 A1Suzhou Forlong Biotechnology Co., Ltd.
- Methods of detecting and treating cerebral aneurysms19 Feb 2026US 2026/0049998 A1University of Pittsburgh—Of the Commonwealth System of Higher Education
Most cited
By later US patents
- Prostaglandin E2 dual variable domain immunoglobulins and uses thereof85US 8,822,645 B2AbbVie Inc. · 2014
- Compositions and methods for achieving immune suppression33US 6,797,263 B2Beth Israel Deaconess Medical Center, Inc. · 2004
- Compositions and methods for achieving immune suppression24US 7,347,995 B2Beth Israel Deaconess Medical Center, Inc. · 2008
- Antibodies to IL-1516US 10,301,384 B2Calypso Biotech SA · 2019
- Methods of developing selective peptide antagonists9US 9,959,384 B2Bioniz, LLC · 2018